Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Short term Debt: 2017

  • Aclaris Therapeutics' Short term Debt was N/A to $590,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $590,000, marking a year-over-year change of. This contributed to the annual value of $590,000 for FY2017, which is N/A change from last year.
  • As of Q4 2017, Aclaris Therapeutics' Short term Debt stood at $590,000.
  • In the past 5 years, Aclaris Therapeutics' Short term Debt ranged from a high of $590,000 in Q4 2017 and a low of $590,000 during Q4 2017.
  • Its 1-year average for Short term Debt is $590,000, with a median of $590,000 in 2017.